Nov 14 |
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
Nov 13 |
Lyra Therapeutics GAAP EPS of -$0.18 beats by $0.02, revenue of $0.2M misses by $0.06M
|
Nov 12 |
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
|
Nov 12 |
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
Oct 15 |
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
|
Sep 27 |
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
|
Aug 15 |
Lyra Therapeutics still sees potential in rhinosinusitis asset despite setbacks
|
Aug 14 |
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
|
Aug 14 |
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
Jul 15 |
Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1?
|